Researchers combined a microfluidic technology called the CTC-iChip with digital PCR to potentially improve cancer detection in hepatocellular carcinoma patients.
University of Cambridge researchers found that the portion of tumor DNA in patients' blood could predict treatment response and time to disease progression.
Esoterix sued Myriad in September, claiming that its myRisk Hereditary Cancer panel and services directly infringe four patents it has exclusively licensed.
Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.
A University of Michigan Health System team showed that heat fragmentation leads to increased detection of a G-to-A mutation of the KRAS gene in vendor-purchased DNA.
Two Boston-based researchers shared methods for detecting circulating nucleic acid biomarkers for potential use in cancer diagnosis and monitoring.
Bio-Rad reported $570.6 million in revenues in Q4, a 5 percent drop year over year but a 3 percent increase on a currency-neutral basis.
Digital PCR can better detect low levels of chronic myeloid leukemia in patients than other PCR-based approaches, according to Imperial College London researchers.
A majority of respondents said liquid biopsy is poised to become a widely used tool for assessing cancer mutations within the next one to four years, with NGS-based analysis preferred over other testing modalities.
In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.